Siglec-7 mRNA levels were substantially higher in aggressive molecular subtypes of breast cancer, with particularly strong increases in HER2+ and TNBC subtypes in TCGA cohort, and the Claudin-low subtype in METABRIC patients (Figures 2A, H). This evidence concerns the gene ERBB2 and breast carcinoma.